We expect [hyomun financial newspaper reporters standing in Korea] become a global innovator item to radically change the look of our lives, even in the aging society 'smartphones around the world to change the way of life laid as a "inboard four' .'- Lee Ungyeol Kolon group Chairman.
Lee Ungyeol Kolon Group Chairman 5 days to find the world's first gene therapy arthritis cells invoked's production base Kolon Life Science Chungju Plant, we went to the local business scene management. Invoke Corp. is placed in front of the current drug approval items.
In this day factory employees celebrate the successful journey of four inboard development ahead of production in 19 years of development and laid the event is a talk show, invoking four ceremonies. The event dwaeteumyeo proceeds from the lively atmosphere, such as encouraging employees who have to share the best practices developed in the meantime, quietly dedicated to the development was also attended by the president.
The President said that direct participation in the program detailing the means for invoking's self, especially on a blackboard "buy me invoke 981,103. He even called "inboard four projects reviewed was a report of this day receives a November 1998 three days had really a lot of trouble in reporting that the chances of success slim, saying," However, the success probability is 0.00001% think the future of the group, moved boldly to run I could not wait until 'he recalled.
Followed by 'invoking' s Birth of 981,103 was for me was the number of another success 'saying''m tasks that are expanded to Chungju Plant, the annual output to 1 additional 10 million doses in the Gulf dose promotion proceed without a hitch until the last upcoming invoicing Let's prepare for times ahead, he added.
Briefly administered the inboard living cells with a growth factor that promotes differentiation of normal allogeneic bone cells and cells of the human knee joint space by injection into a biopharmaceuticals for the treatment of osteoarthritis. In Korea, in July last year had to apply for new drug products authorized in the KFDA, it has also signed a technology export contract of 500 billion won successive maximums in November last year, the Japanese Mitsubishi Tanabe Pharmaceutical and danilguk standards. Successfully finished a Phase II clinical testing in the United States plans to soon enter the phase III clinical trials.
Daily Economic News Finance FNTIMES - commercial reprint, copy, distribute prohibited purposes under the Copyright Act
Copyright ⓒ Korea's Financial News & FNTIMES.com
